NASDAQ:CELG - Celgene Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $93.19 -0.48 (-0.51 %) (As of 04/24/2019 12:19 PM ET)Previous Close$93.67Today's Range$93.0250 - $93.8852-Week Range$58.59 - $95.44Volume2.02 million shsAverage Volume11.61 million shsMarket Capitalization$65.46 billionP/E Ratio12.25Dividend YieldN/ABeta1.71 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA, a small molecule inhibitor of the isocitrate dehydrogenase 2 to treat acute myeloid leukemia (AML); VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; and THALOMID to treat patients with MM and erythema nodosum leprosum. Its clinical stage products comprise OTEZLA to treat various immune-inflammatory diseases; luspatercept for the treatment of patients with beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; CC-92480 to treat multiple myeloma; and durvalumab, an anti-PD-L1 antibody for hematological cancers. The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Vividion Therapeutics, Inc.; Jounce Therapeutics, Inc.; Prothena Corporation plc; Zymeworks Inc.; and Evotec AG, as well as strategic collaborations with Skyhawk Therapeutics, Inc., Dragonfly Therapeutics, Inc., Obsidian Therapeutics, Philogen S.p.A., and Kyn Therapeutics. The company was founded in 1980 and is headquartered in Summit, New Jersey. Receive CELG News and Ratings via Email Sign-up to receive the latest news and ratings for CELG and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:CELG Previous Symbol CUSIP15102010 CIK816284 Webwww.celgene.com Phone908-673-9000Debt Debt-to-Equity Ratio3.21 Current Ratio2.23 Quick Ratio2.12Price-To-Earnings Trailing P/E Ratio12.25 Forward P/E Ratio9.31 P/E Growth0.43 Sales & Book Value Annual Sales$15.28 billion Price / Sales4.28 Cash Flow$8.8165 per share Price / Cash Flow10.57 Book Value$8.79 per share Price / Book10.60Profitability EPS (Most Recent Fiscal Year)$7.61 Net Income$4.05 billion Net Margins26.48% Return on Equity114.66% Return on Assets16.34%Miscellaneous Employees8,852 Outstanding Shares702,450,000Market Cap$65.46 billion Next Earnings Date5/3/2019 (Estimated) OptionableOptionable Celgene (NASDAQ:CELG) Frequently Asked Questions What is Celgene's stock symbol? Celgene trades on the NASDAQ under the ticker symbol "CELG." When did Celgene's stock split? How did Celgene's stock split work? Celgene shares split on the morning of Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly created shares were distributed to shareholders after the market closes on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene stock prior to the split would have 200 shares after the split. How will Celgene's stock buyback program work? Celgene declared that its board has approved a stock buyback plan on Thursday, May 24th 2018, which permits the company to buyback $3,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to buy up to 5.4% of its shares through open market purchases. Shares buyback plans are generally an indication that the company's leadership believes its shares are undervalued. How were Celgene's earnings last quarter? Celgene Co. (NASDAQ:CELG) posted its earnings results on Thursday, January, 31st. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.32 by $0.07. The biopharmaceutical company earned $4.04 billion during the quarter, compared to analysts' expectations of $3.98 billion. Celgene had a net margin of 26.48% and a return on equity of 114.66%. During the same period last year, the business earned $2.00 earnings per share. View Celgene's Earnings History. When is Celgene's next earnings date? Celgene is scheduled to release their next quarterly earnings announcement on Friday, May 3rd 2019. View Earnings Estimates for Celgene. What guidance has Celgene issued on next quarter's earnings? Celgene issued an update on its FY19 earnings guidance on Thursday, January, 31st. The company provided earnings per share guidance of $10.60-10.80 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $10.66. The company issued revenue guidance of $17-17.2 billion, compared to the consensus revenue estimate of $17.11 billion.Celgene also updated its FY 2019 guidance to $10.60-10.80 EPS. What price target have analysts set for CELG? 24 brokerages have issued 12 month price objectives for Celgene's stock. Their forecasts range from $77.00 to $129.00. On average, they expect Celgene's stock price to reach $99.4318 in the next twelve months. This suggests a possible upside of 6.7% from the stock's current price. View Analyst Price Targets for Celgene. What is the consensus analysts' recommendation for Celgene? 24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celgene in the last year. There are currently 16 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Celgene. What are Wall Street analysts saying about Celgene stock? Here are some recent quotes from research analysts about Celgene stock: 1. According to Zacks Investment Research, "Celgene’s key growth driver, Revlimid continues to drive revenues. Robust performance of psoriasis drug, Otezla is also boosting performance. Investors are focusing on the company’s recent merger agreement with Bristol-Myers Squibb Company. Per the terms, Celgene shareholders will receive 1.0 share of Bristol-Myers and $50.00 in cash for each share held. Though the acquisition is yet to be approved, the company will get a respite from the same, having faced a series of pipeline setbacks in recent times. Meanwhile, Celgene is also working on label expansion of drugs like Pomalyst/Imnovid, Abraxane and Otezla, among others. The company is focused on the next cycle of innovation with five late-stage candidates — ozanimod, fedratinib, luspatercept, liso-cel and bb2121 — all of which are expected to be launched by the end of 2020. Shares have outperformed the industry in the past three months." (4/3/2019) 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $100 12-month price target. Celgene reported a strong 4Q this morning and issued full year 2019 guidance. 4Q revs of ~$4B beat us and consensus on the top line, while adj. EPS of $2.39 also came in above us and consensus at $2.33 and $2.32. Base business trends were surprisingly strong, and management reiterated timelines for all five late- stage pipeline products on track for approval by the end of 2020. We think the key takeaway from the call was that commercial and pipeline execution appear to be back on track with a clear line of sight to the Bristol (BMY, NC) deal closing in 3Q19. We think guidance for 2019 seems conservative." (1/31/2019) 3. Mizuho analysts commented, "We updated our model post the 2Q18 earnings call. Here are the key changes we made: ===Upward Revisions=== 1. bb2121. Added bb2121 to pipeline section of the model ($1Bn in risk- adjusted peak sales to CELG vs consensus of $900MM) 2. Luspatercept. Increased POS from 67% to 90% on the back of the recent positive Ph 3 results. (peak risk-adj sales now of $1Bn, ex-royalty to XLRN …. consensus at $850MM) ===Downward Revisions=== 3. Ozanimod MS. Trimmed peak risked adjusted sales from $1.3Bn to $1.1Bn. In total, across all 3 indications (MS, UC, CD), we carry $2.8Bn (vs consensus of $2.5Bn)." (7/31/2018) 4. Cowen Inc analysts commented, "We will be hosting a conference call with neurologist to discuss and TD-9855. Theravance is evaluating 1/2 trial in patients with . Results are expected to be available this month." (7/10/2018) Has Celgene been receiving favorable news coverage? News coverage about CELG stock has been trending somewhat negative on Wednesday, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Celgene earned a coverage optimism score of -1.4 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the stock's share price in the near future. Are investors shorting Celgene? Celgene saw a decrease in short interest in March. As of March 29th, there was short interest totalling 14,608,028 shares, a decrease of 21.1% from the March 15th total of 18,510,597 shares. Based on an average daily trading volume, of 11,064,155 shares, the days-to-cover ratio is currently 1.3 days. Approximately 2.1% of the shares of the company are short sold. View Celgene's Current Options Chain. Who are some of Celgene's key competitors? Some companies that are related to Celgene include Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Novo Nordisk A/S (NVO), AbbVie (ABBV), Sanofi (SNY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Shire (SHPG) and Zoetis (ZTS). What other stocks do shareholders of Celgene own? Based on aggregate information from My MarketBeat watchlists, some companies that other Celgene investors own include Akorn (AKRX), Gilead Sciences (GILD), NVIDIA (NVDA), Bank of America (BAC), Skechers USA (SKX), Alibaba Group (BABA), Integrated Device Technology (IDTI), Netflix (NFLX), Micron Technology (MU) and Walt Disney (DIS). Who are Celgene's key executives? Celgene's management team includes the folowing people: Mr. Mark J. Alles, Chairman & CEO (Age 60)Mr. Peter N. Kellogg, Exec. VP & Chief Corp. Strategy Officer (Age 63)Dr. S. J. Rupert Vessey, Pres of Research & Early Devel. (Age 54)Mr. David V. Elkins, Exec. VP & CFOMr. Aijaz Tobaccowalla, Sr. VP and Chief Digital & Information Officer (Age 52) Who are Celgene's major shareholders? Celgene's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Douglas Lane & Associates LLC (0.11%), Strs Ohio (0.09%), LGT Capital Partners LTD. (0.08%), Factory Mutual Insurance Co. (0.07%), Gateway Investment Advisers LLC (0.07%) and Bourne Lent Asset Management Inc. (0.06%). Company insiders that own Celgene stock include Ernest Mario, Gilla Kaplan, James J Loughlin, John H Weiland, Mark J Alles, Michael A Friedman, Michael D Casey, Robert J Hugin, Rupert Vessey and Terrie Curran. View Institutional Ownership Trends for Celgene. Which institutional investors are selling Celgene stock? CELG stock was sold by a variety of institutional investors in the last quarter, including Loring Wolcott & Coolidge Fiduciary Advisors LLP MA, Global Thematic Partners LLC, Factory Mutual Insurance Co., Retirement Systems of Alabama, Bristol John W & Co. Inc. NY, PGGM Investments, Gofen & Glossberg LLC IL and Calamos Advisors LLC. Company insiders that have sold Celgene company stock in the last year include Ernest Mario, Gilla Kaplan, James J Loughlin and Michael D Casey. View Insider Buying and Selling for Celgene. Which institutional investors are buying Celgene stock? CELG stock was purchased by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC, First Manhattan Co., Pacer Advisors Inc., Havens Advisors LLC, Tibra Equities Europe Ltd, Financial Advantage Inc., Cohen Klingenstein LLC and Meeder Asset Management Inc.. Company insiders that have bought Celgene stock in the last two years include Ernest Mario, John H Weiland and Mark J Alles. View Insider Buying and Selling for Celgene. How do I buy shares of Celgene? Shares of CELG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Celgene's stock price today? One share of CELG stock can currently be purchased for approximately $93.21. How big of a company is Celgene? Celgene has a market capitalization of $65.48 billion and generates $15.28 billion in revenue each year. The biopharmaceutical company earns $4.05 billion in net income (profit) each year or $7.61 on an earnings per share basis. Celgene employs 8,852 workers across the globe. What is Celgene's official website? The official website for Celgene is http://www.celgene.com. How can I contact Celgene? Celgene's mailing address is 86 MORRIS AVENUE, SUMMIT NJ, 07901. The biopharmaceutical company can be reached via phone at 908-673-9000 or via email at [email protected] MarketBeat Community Rating for Celgene (NASDAQ CELG)Community Ranking: 3.7 out of 5 ( )Outperform Votes: 1,955 (Vote Outperform)Underperform Votes: 719 (Vote Underperform)Total Votes: 2,674MarketBeat's community ratings are surveys of what our community members think about Celgene and other stocks. Vote "Outperform" if you believe CELG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CELG will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/24/2019 by MarketBeat.com StaffFeatured Article: What is the Moving Average Convergence Divergence (MACD) oscillator?